Lantheus Announces Presentation of New Patient Outcomes Data for DEFINITY at the American Society of Echocardiography 2019 Annual Scientific Sessions

Lantheus Holdings, Inc. (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced new clinical outcomes data for DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension demonstrating the positive impact of contrast echocardiography with DEFINTY in intensive care unit (ICU) patients as compared to ICU patients who received echocardiography without contrast. The data will be presented during a poster session today at 9:00 a.m.-4:00 p.m. PT at the American Society of Echocardiography (ASE 2019) Annual Scientific Sessions. DEFINITY is a cardiovascular ultrasound contrast agent currently indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.¹

The study findings show that DEFINITY-enhanced echocardiography in the ICU setting, in comparison with non-contrast transthoracic echocardiography (TTE), is associated with lower rates of subsequent TTE and transesophageal echocardiography (TEE) during the index hospitalization, shorter ICU length of stay, and significant changes in use of vasoactive medications.

“These clinical outcomes data are important and reveal that use of contrast echocardiography with DEFINITY is associated with reduced subsequent cardiac ultrasound testing and reduced length of stay for ICU patients,” said Michael L. Main, M.D., lead investigator and co-executive medical director of Saint Luke’s Mid America Heart Institute in Kansas City. “Patients in critical care settings are often difficult to image due to their medical conditions, and as a result, suboptimal images are obtained up to 25 percent of the time, impacting diagnostic accuracy and confidence. The use of contrast enhanced echocardiography in obtaining accurate and interpretable images is critical in influencing patient diagnosis, treatment, and clinical outcomes.”

The Premier Healthcare Database was analyzed to identify ICU patients receiving DEFINITY as compared to no use of contrast during the initial rest TTE in ICU patients. Primary outcomes of interest were subsequent TTE and TEE during the index hospitalization and ICU length of stay. The data results from the retrospective observational study, with patient data captured between January 1, 2009 and September 30, 2015, showed a total of 1,538,864 patients from 773 hospitals were identified as undergoing resting TTE in the ICU with DEFINITY in 51,141 (3.3%) patients and no contrast agent use in 1,487,723 (96.7%) patients. After adjusting for patient, clinical, and hospital characteristics, an adjusted analysis for subsequent TTE and TEE showed that during the index hospitalization, patients in the DEFINITY cohort were less likely to undergo a subsequent TTE or TEE as compared to those in the no contrast cohort (odds ratio=0.704 for TTE, odds ratio=0.841 for TEE; p<0.0001 for both). Adjusted mean ICU length of stay for the DEFINITY cohort was approximately 10% shorter than that of the no contrast cohort (4.15 vs. 4.59 days, p<0.0001). Compared to the no contrast cohort, patients in the DEFINITY cohort were more likely to start use of parenteral inotrope (3.8% vs. 2.4%), end use of parenteral inotrope (0.6% vs. 0.3%), start use of parenteral pressor (12.8% vs. 11.6%) and end use of parenteral pressor (4.3% vs. 3.2%) on the day of, or one day after the index TTE (all p<0.0001).